4 most recent filings and news items mentioning TENX. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/TENX/news?limit=20"
Pull TENX filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayTenax Therapeutics reports that its Phase 3 LEVEL study for TNX-103 did not meet its primary endpoint, though exploratory analysis showed reduced NT-proBNP and improved walk distances in patients with higher disease burden.
View filing at SEC.gov →Company reported $12.9M in R&D and $5.9M in SG&A, with net loss of $17.8M. Aiming for topline phase 3 data in August and full enrollment of LEVEL-2 by end-2027.
View filing at SEC.gov →Tenax confirmed it will present its Phase 3 LEVEL trial results at the ESC Congress 2026. This presentation reviews levosimendan's potential to treat PH-HFpEF.
View filing at SEC.gov →Tenax Therapeutics amended the bonus structure in CEO Christopher Giordano's employment agreement. The revision removes caps on payouts, potentially incentivizing stronger performance and alignment.
View filing at SEC.gov →